Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing

@article{Bauss2004IbandronateIO,
  title={Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing},
  author={Frieder Bauss and R Graham Russell},
  journal={Osteoporosis International},
  year={2004},
  volume={15},
  pages={423-433}
}
Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced compliance by patients. The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommended… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

Biodistribution and plasma protein binding of zoledronic acid.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2008
VIEW 4 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED

Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy.

  • Biochemical and biophysical research communications
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 106 REFERENCES

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1993
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis

PJ Meunier, RR Recker, +3 authors P Mahoney
  • 2003
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…